

Supplementary Table 1. Clinical characteristics of men with prostate cancer at cancer diagnosis (N=92,105).

	Prostate cancer cohort 92,105 n (%)	
	n	%
TNM stage		
T1	47,658	51.7
T2	27,389	29.7
T3	14,342	15.6
T4	2,612	2.8
Missing	104	0.1
N0	17,789	19.3
N1	2725	3.0
NX	71,445	77.6
Missing	146	0.2
M0	57,637	62.6
M1	7310	7.9
MX	26,990	29.3
Missing	168	0.2
Prostate cancer risk group		
Low	26,251	28.5
Intermediate	29,235	31.7
High	19,523	21.2
Regionally metastasized	5294	5.7
Distant metastases	10,615	11.5
Missing	1187	1.3
PSA at diagnosis (mg/l)		
<3	3331	3.6
3–10	49,178	53.4
11–50	26,284	28.5
≥51	11,822	12.8
Missing	1490	1.6
Mean (SD)	72.7	565.6
Median (Q1–Q3)	8.8	5.4–20.0

PSA, prostate-specific antigen; TNM, tumour-node-metastasis

Supplementary Table 2. Five-year incidence proportion (95% CI) of first VTE among men with and without prostate cancer.

Time (months)	Prostate cancer cohort N=92,1015		Comparison cohort N=466,241		IPR (95% CI)
	First incident VTE cases, N	Incidence proportion (95% CI)	First incident VTE cases, N	Incidence proportion (95% CI)	
0	0		0		
6	453	0.49 (0.45–0.54)	908	0.19 (0.18–0.21)	2.53 (2.26–2.83)
12	790	0.86 (0.80–0.92)	1858	0.40 (0.38–0.42)	2.15 (1.98–2.34)
18	1 045	1.13 (1.07–1.21)	2721	0.58 (0.56–0.61)	1.94 (1.81–2.09)
24	1 275	1.38 (1.31–1.46)	3524	0.76 (0.73–0.78)	1.83 (1.72–1.95)
30	1 473	1.60 (1.52–1.68)	4270	0.92 (0.89–0.94)	1.75 (1.65–1.85)
36	1 688	1.83 (1.75–1.92)	4986	1.07 (1.04–1.10)	1.71 (1.62–1.81)
42	1 857	2.04 (1.95–2.13)	5651	1.21 (1.18–1.24)	1.66 (1.58–1.75)
48	2 009	2.18 (2.09–2.28)	6220	1.33 (1.30–1.37)	1.63 (1.56–1.72)
54	2 156	2.34 (2.24–2.44)	6774	1.45 (1.42–1.49)	1.61 (1.54–1.69)
60	2 277	2.47 (2.37–2.57)	7245	1.55 (1.52–1.59)	1.59 (1.52–1.67)

CI, confidence interval; IPR, incidence proportion ratio; VTE, venous thromboembolism

Supplementary Table 3. Five-year incidence proportion (95% CI) of **first DVT** among men with and without prostate cancer.

Time (months)	Prostate cancer cohort N=92,1015		Comparison cohort N=466,241		IPR (95% CI)
	First incident DVT cases, N	Incidence proportion (95% CI)	First incident DVT cases, N	Incidence proportion (95% CI)	
0	0		0		
6	240	0.26 (0.23–0.30)	487	0.10 (0.10–0.11)	2.49 (2.14–2.91)
12	422	0.46 (0.42–0.50)	986	0.21 (0.20–0.22)	2.17 (1.93–2.43)
18	558	0.61 (0.56–0.66)	1454	0.31 (0.30–0.33)	1.94 (1.76–2.14)
24	659	0.72 (0.66–0.77)	1880	0.40 (0.39–0.42)	1.77 (1.62–1.94)
30	765	0.83 (0.77–0.89)	2273	0.49 (0.47–0.51)	1.70 (1.57–1.85)
36	855	0.93 (0.87–0.99)	2641	0.57 (0.55–0.59)	1.64 (1.52–1.77)
42	940	1.02 (0.96–1.09)	2997	0.64 (0.62–0.67)	1.59 (1.48–1.71)
48	1020	1.11 (1.04–1.18)	3297	0.71 (0.68–0.73)	1.57 (1.46–1.68)
54	1105	1.20 (1.13–1.27)	3589	0.77 (0.74–0.80)	1.56 (1.46–1.67)
60	1171	1.27 (1.20–1.35)	3835	0.82 (0.80–0.85)	1.55 (1.45–1.65)

CI, confidence interval; DVT, deep vein thrombosis; IPR, incidence proportion ratio

Supplementary Table 4. Five-year incidence proportion (95% CI) of first PE among men with and without prostate cancer.


Time (months)	Prostate cancer cohort N=92,1015		Comparison cohort N=466,241		IPR (95% CI)
	First incident PE cases, N	Incidence proportion (95% CI)	First incident PE cases, N	Incidence proportion (95% CI)	
0	0		0		
6	193	0.21 (0.18–0.24)	388	0.08 (0.08–0.09)	2.52 (2.12–2.99)
12	343	0.37 (0.33–0.41)	803	0.17 (0.16–0.18)	2.16 (1.91–2.45)
18	455	0.49 (0.45–0.54)	1188	0.25 (0.24–0.27)	1.94 (1.74–2.16)
24	581	0.63 (0.58–0.68)	1554	0.33 (0.32–0.35)	1.89 (1.72–2.08)
30	670	0.73 (0.67–0.78)	1907	0.41 (0.39–0.43)	1.78 (1.63–1.94)
36	791	0.86 (0.80–0.92)	2248	0.48 (0.46–0.50)	1.78 (1.64–1.93)
42	877	0.95 (0.89–1.02)	2558	0.55 (0.53–0.57)	1.74 (1.61–1.87)
48	951	1.03 (0.97–1.10)	2837	0.61 (0.59–0.63)	1.70 (1.58–1.83)
54	1 023	1.11 (1.04–1.18)	3116	0.67 (0.65–0.69)	1.66 (1.55–1.78)
60	1 078	1.17 (1.10–1.24)	3344	0.72 (0.69–0.74)	1.63 (1.52–1.75)

CI, confidence interval; IPR, incidence proportion ratio; PE, pulmonary embolism

Supplementary Table 5. Age-stratified incidence rates of first VTE per 1000 person-years (95% CI) in men with prostate cancer and men without prostate cancer, and HRs (95% CI) comparing the two cohorts.


Age (years)	Prostate cancer cohort N=92,1015	Comparison cohort N=466,241
<60		
Incidence rate of VTE per 1000 person-years (95% CI)	4.56 (4.05–5.13)	2.38 (2.21–2.55)
Crude HR (95% CI)	1.92 (1.67–2.20)	1.0 (reference)
60–64		
Incidence rate of VTE per 1000 person-years (95% CI)	5.20 (4.74–8.72)	3.36 (3.19–3.54)
Crude HR (95% CI)	1.55 (1.39–1.72)	1.0 (reference)
65–69		
Incidence rate of VTE per 1000 person-years (95% CI)	6.32 (5.88–6.80)	4.02 (3.86–4.19)
Crude HR (95% CI)	1.57 (1.44–1.71)	1.0 (reference)
70–74		
Incidence rate of VTE per 1000 person-years (95% CI)	7.24 (6.71–7.84)	4.66 (4.60–4.86)
Crude HR (95% CI)	1.56 (1.42–1.70)	1.0 (reference)
75–79		
Incidence rate of VTE per 1000 person-years (95% CI)	7.92 (7.22–8.67)	5.53 (5.27–5.80)
Crude IRR (95% CI)	1.43 (1.29–1.59)	1.0 (reference)
80–84		
Incidence rate of VTE per 1000 person-years (95% CI)	8.40 (7.46–9.47)	6.11 (5.75–6.49)
Crude HR (95% CI)	1.37 (1.20–1.57)	1.0 (reference)
≥85		
Incidence rate of VTE per 1000 person-years (95% CI)	9.86 (8.45–11.49)	6.88 (6.35–7.45)
Crude HR (95% CI)	1.44 (1.21–1.71)	1.0 (reference)

CI, confidence interval; HR, hazard ratio; VTE, venous thromboembolism



Supplementary Figure 1. Five-year incidence proportion of **first DVT** in the prostate cancer cohort and the comparison cohort.

CI, confidence interval; DVT, deep vein thrombosis; IPR, incidence proportion ratio; RR, rate ratio



Supplementary Figure 2. Five-year incidence proportion of **first PE** among men with and without prostate cancer.

CI, confidence interval; IPR, incidence proportion ratio; PE, pulmonary embolism; RR, rate ratio